3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
19
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Follicular
12
Lymphoma, Non-Hodgkin
11
Lymphoma, Mantle-Cell
8
Lymphoma, B-Cell, Marginal Zone
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Waldenstrom Macroglobulinemia
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large-Cell, Anaplastic
3
Burkitt Lymphoma
3
Lymphoma, B-Cell
2
Leukemia
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Orbital lymphoma
1
Oncology Patients Receiving Chemotherapy
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Graft vs Host Disease
1
Interventions
Rituximab
4
Cyclophosphamide
4
ponatinib
2
Vorinostat
2
Vincristine
2
Prednisone
2
Etoposide
2
Doxorubicin
2
Brentuximab Vedotin
2
Bortezomib
2
tetulomab tetraxetan lu-177
1
pembrolizumab
1
ibrutinib
1
ibritumomab tiuxetan
1
fludarabine
1
durvalumab
1
cobomarsen
1
acalabrutinib
1
Melphalan
1
Lutetium
1
Lenalidomide
1
KW-2478
1
Imatinib Mesylate
1
Ifosfamide
1
Hsp90 inhibitor KU757
1
Cytarabine
1
Carmustine
1
Carboplatin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Immune System Diseases
×
ibritumomab tiuxetan
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts